People type zepbound not worth it plateau the night before the card runs again. The shot went in. The month got paid. The scale did not move the way the ad implied.
We believe you.
Public reviews of the big GLP-1 subscription programs pile up around bills that did not match the ad, and around membership fees stacked on the drug after a cheap intro. Boxes never show. Chats never produce a person. Cancel is its own fight. A smaller share say the medicine did not change anything they could feel. Angry people post. Satisfied people mostly do not. You keep paying, the number sits still, and there is no one to tell you whether the next charge is still a plan.
We believe you.
If no one reviews the month, you pay either way.
When a Zepbound not worth it plateau still needs a look
Zepbound starts at 2.5 mg once a week. That first dose is for getting started. The FDA label says it is not a maintenance dose. The climb is 2.5 mg steps after at least four weeks on the current amount, and maintenance is 5 mg, 10 mg, or 15 mg. The main obesity trial spent 20 weeks getting people up. Nausea is common on the way. A clinician may hold a step. If you are still on the first or second pen, you have not given the trial dose a fair run. You have been paying for the ramp.
If you already lost a lot and the line went flat, that can be the body settling. NIDDK notes that weight loss is hard to keep, and that some medicines are used to help hold it. Holding the weight you have may be the work now. Stopping is a medical choice with a known pattern.
In the SURMOUNT-4 trial, adults on tirzepatide lost about 21 percent of their weight over 36 weeks. Then half stayed on the drug and half switched to placebo. Over the next year, people who stayed on lost a little more. People who stopped gained about 14 percent from that point. Almost 9 in 10 who kept the drug held on to most of the loss. About 1 in 6 of the people who stopped did.
The STEP 1 follow-up on weekly semaglutide found the same direction. After 68 weeks of treatment, people who came off regained about two-thirds of the lost weight by one year.
You may be paying to keep what you already lost. Some people still decide the monthly charge is too high. That is a real call. Make it with the regain risk on the table, not as a mood after one loud Wednesday.
If you have not lost much at all, the next month needs a different look. Clinics usually call someone a non-responder when they stay under 5 percent of starting weight after time on the highest dose they can tolerate. NIDDK says losing 5 percent over about six months may be a fair first goal. In the FDA obesity studies of Wegovy, about 14 percent of people without diabetes stayed under that line. On Zepbound, about 9 to 15 percent did, depending on the dose. Put those trials together and you land in a 10 to 20 percent band. Some people on a full dose still do not lose 5 percent. Many people searching this have not reached that dose.
Missed shots can look like a dead drug. So can a dose you cannot keep down. So can a program with no human to review the month.
Ask for a review before you pay for another month of the same plan.
What to ask before you pay another month
Bring the calendar and the statements.
Ask what dose you are on and how many weeks you have been at it. Ask whether this is still the climb. Ask how they want weight tracked so one Wednesday does not get counted as a month. Ask what they would change if the next four weeks look like the last four. Dose review is one option. Checking missed doses is another. Other medicines, sleep, and alcohol belong in that visit if they have not been. Switching inside this drug family is a medical decision. Stopping is too.
This page cannot pick among those.
At Living+ compounded semaglutide is 197 dollars a month and tirzepatide is 247, flat. Each month includes a personal coach. There is no separate visit fee. The price does not rise with the dose. If a clinician declines you, the charge is refunded. Compounded copies are not FDA-approved Wegovy or Zepbound. Some people still do not lose 5 percent. Some people stall after they have already lost. Talk to your provider before you pay another month of a plan no one has looked at.
Prices were accurate at the time this was published.
Sources
- FDA: Zepbound (tirzepatide) prescribing information, starting dose, maintenance doses, and Study 1 5% responders
- DailyMed: Zepbound (tirzepatide) dosage and administration
- FDA: Wegovy (semaglutide) prescribing information, Study 2 5% responders
- Aronne et al., Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4), PMC10714284
- Wilding et al., Weight regain after withdrawal of semaglutide: The STEP 1 trial extension, PMC9542252
- Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), PubMed 35658024
- NIDDK: Treatment for Overweight and Obesity, 5% goal and medicines to maintain weight loss
- FDA: Compounding and the FDA, compounded drugs are not FDA-approved
See what a Living+ plan costs and whether it fits.
